More on RANI

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (+72.2% Growth)
- Ratings (10.0 Score)

Upcoming Events

- Earnings (8/6/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Rani Therapeutics (NQ:RANI)
Delayed: 0.70 +0.03 (4.48%)
Prev. Close $0.67  
Open$0.66 
52 Wk High$ 
52 Wk Low$ 
Day High$0.73 
Day Low$0.65 
P/E N/A  
EPS$ 
Volume1,195,568 


Jul 15, 2026 05:10 PM Form S-8 Rani Therapeutics Holdin
Jul 15, 2026 08:00 AM Rani Therapeutics oral obesity drug tops subcutaneous exposure in Phase 1a
Jul 15, 2026 08:00 AM Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing
Jul 9, 2026 04:06 PM Rani Therapeutics and PegBio enter obesity drug collaboration
Jul 9, 2026 04:05 PM Rani Therapeutics Announces Research and Development Collaboration with PegBio to Expand Obesity Pipeline Across Multiple Novel Candidates
Jul 8, 2026 04:05 PM Form 3 Rani Therapeutics Holdin For: Jun 29 Filed by: Maestas Nicholas
Jun 30, 2026 06:02 AM Form 8-K Rani Therapeutics Holdin For: Jun 24
Jun 29, 2026 08:02 AM Rani Therapeutics names Nicholas Maestas as CFO
Jun 29, 2026 08:00 AM Rani Therapeutics Appoints Nicholas Maestas as Chief Financial Officer
Jun 5, 2026 06:20 PM Form 4 Rani Therapeutics Holdin For: Jun 03 Filed by: McKinley Kate
View All Articles

Entities mentioned with RANI

View All Entities